309 related articles for article (PubMed ID: 12142553)
1. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
Li Q; Yu B; Grover AC; Zeng X; Chang AE
J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
[TBL] [Abstract][Full Text] [Related]
2. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
Aruga A; Aruga E; Cameron MJ; Chang AE
J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
[TBL] [Abstract][Full Text] [Related]
3. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
7. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
8. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
9. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
10. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
12. Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Chang AE
J Immunother; 1997 Mar; 20(2):138-45. PubMed ID: 9087386
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells.
Wahl WL; Sussman JJ; Shu S; Chang AE
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):242-50. PubMed ID: 8061896
[TBL] [Abstract][Full Text] [Related]
15. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
16. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
Li Q; Furman SA; Bradford CR; Chang AE
Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.
Hilchey SP; De A; Rimsza LM; Bankert RB; Bernstein SH
J Immunol; 2007 Apr; 178(7):4051-61. PubMed ID: 17371959
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of CD4 and CD8 engagement on the development of cytokine profiles of murine CD4+ and CD8+ T lymphocytes.
Campbell SB; Komata T; Kelso A
Immunology; 2000 Mar; 99(3):394-401. PubMed ID: 10712669
[TBL] [Abstract][Full Text] [Related]
20. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
